Global Cancer Biopsy Market

Cancer Biopsy Comprehensive Study by Type (Incisional Biopsy, Excisional Biopsy, Needle Biopsy), Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Others), Product (Instruments, Kits and Consumables, Services), End User (Laboratories, Hospitals, Physician Laboratories, Research Centers, Others) Players and Region - Global Market Outlook to 2027

Cancer Biopsy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cancer Biopsy?
A cancer biopsy is a procedure that involves removing a piece of tissue or a sample of cells from the body to be tested in a laboratory. A cancer biopsy may be performed if you are experiencing certain signs and symptoms or if your doctor has identified an area of concern. A biopsy can tell you if you have cancer or another condition. Imaging tests, such as CT scans or MRIs, can help detect masses or irregular tissue, but they can't tell the difference between cancerous and non-cancerous cells. The only way to diagnose most cancers is to perform a biopsy to collect cells for further examination.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledQiagen N.V. (Germany), Illumina, Inc. (United States), ANGLE Plc (United Kingdom), BD (United States), Myriad Genetics (United States), Hologic, Inc. (United States), Biocept, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Danaher (United States) and Roche Holding AG (Switzerland)


The study covers a detailed analysis segmented by key business segments i.e. by type (Incisional Biopsy, Excisional Biopsy and Needle Biopsy) , by application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cancer Biopsy market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Cancer Biopsy market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Qiagen N.V. (Germany), Illumina, Inc. (United States), ANGLE Plc (United Kingdom), BD (United States), Myriad Genetics (United States), Hologic, Inc. (United States), Biocept, Inc. (United States), Thermo Fisher Scientific, Inc. (United States), Danaher (United States) and Roche Holding AG (Switzerland).

Market Overview:
On 18th August 2021, Illumina, Inc. announced the acquisition of GRAIL, a healthcare company focused on life-saving early detection of multiple cancers but will keep GRAIL separate while the European Commission conducts its ongoing regulatory review. The global leader in DNA sequencing, Illumina, first announced its intention to acquire GRAIL, reuniting Illumina with GRAIL after it was spun off. The Galleri blood test from GRAIL detects 50 different cancers before they cause symptoms. The acquisition of GRAIL by Illumina will accelerate global access and adoption of this life-saving test.
Clinical Genomics has extensive experience in the detection and management of colorectal cancer (CRC) patients using liquid biopsy. A circulating tumor DNA (ctDNA) assay has been developed by a CLIA-certified and CAPaccredited laboratory in Bridgewater, NJ for the management of patients previously diagnosed with CRC. This assay is a laboratory-developed test (LDT) that is subject to federal and state laws and regulations. Furthermore, we have developed a ctDNA screening test for CRC and are working with the FDA to obtain Premarket Approval for use of this test in the US market. Both assays detect abnormal methylation in several genes that are hypermethylated in CRC tissue and detectable in plasma as ctDNA.
Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to maintain current market competition. Furthermore, a detailed competitive benchmarking of the players operating in the global liquid biopsy market has been performed to assist the reader in understanding how players stack up against one another, presenting a clear market landscape. Furthermore, comprehensive competitive strategies such as partnerships, agreements, and collaborations will help the reader understand the market's untapped revenue pockets.

Cancer Biopsy Market Dynamics:
AttributesDetails
Growth Drivers
  • Improving Healthcare Infrastructure
  • Increasing Healthcare Spending
  • Increasing Number of Chronic Medical Sicknesses
Major Trends
  • Needle-based Cancer Biopsy Instruments are in high demand due to their ability to collect samples from the soft tissues of internal organs such as the breasts, kidneys, and lungs
Restraints
  • High Cost of Cancer Biopsy
  • Lack of Awareness of Cancer Biopsy among Certain Set of Population
Road Blocks / Challenges
  • Presence of Competitors
  • Lack of Skilled Professionals
Gaps & Opportunities
  • Untapped Market of Developing Countries


Key highlights of the Global Cancer Biopsy market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Cancer Biopsy market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Cancer Biopsy market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Cancer Biopsy Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cancer Biopsy market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Cancer Biopsy market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Cancer Biopsy Providers, Research institutes, Physicians and surgeons, Healthcare service providers and clinical research organizations, Market research and consulting firms, Government Bodies, End-Users and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Incisional Biopsy
  • Excisional Biopsy
  • Needle Biopsy
By Application
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancers
  • Lung Cancers
  • Prostate Cancers
  • Others
By Product
  • Instruments
  • Kits and Consumables
  • Services

By End User
  • Laboratories
  • Hospitals
  • Physician Laboratories
  • Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Improving Healthcare Infrastructure
      • 3.2.2. Increasing Healthcare Spending
      • 3.2.3. Increasing Number of Chronic Medical Sicknesses
    • 3.3. Market Challenges
      • 3.3.1. Presence of Competitors
      • 3.3.2. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Needle-based Cancer Biopsy Instruments are in high demand due to their ability to collect samples from the soft tissues of internal organs such as the breasts, kidneys, and lungs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Biopsy, by Type, Application, Product, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Cancer Biopsy (Value)
      • 5.2.1. Global Cancer Biopsy by: Type (Value)
        • 5.2.1.1. Incisional Biopsy
        • 5.2.1.2. Excisional Biopsy
        • 5.2.1.3. Needle Biopsy
      • 5.2.2. Global Cancer Biopsy by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Colorectal Cancer
        • 5.2.2.3. Cervical Cancers
        • 5.2.2.4. Lung Cancers
        • 5.2.2.5. Prostate Cancers
        • 5.2.2.6. Others
      • 5.2.3. Global Cancer Biopsy by: Product (Value)
        • 5.2.3.1. Instruments
        • 5.2.3.2. Kits and Consumables
        • 5.2.3.3. Services
      • 5.2.4. Global Cancer Biopsy by: End User (Value)
        • 5.2.4.1. Laboratories
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Physician Laboratories
        • 5.2.4.4. Research Centers
        • 5.2.4.5. Others
      • 5.2.5. Global Cancer Biopsy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cancer Biopsy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Qiagen N.V. (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Illumina, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ANGLE Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BD (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myriad Genetics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hologic, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocept, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Danaher (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Roche Holding AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Biopsy Sale, by Type, Application, Product, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Cancer Biopsy (Value)
      • 7.2.1. Global Cancer Biopsy by: Type (Value)
        • 7.2.1.1. Incisional Biopsy
        • 7.2.1.2. Excisional Biopsy
        • 7.2.1.3. Needle Biopsy
      • 7.2.2. Global Cancer Biopsy by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Colorectal Cancer
        • 7.2.2.3. Cervical Cancers
        • 7.2.2.4. Lung Cancers
        • 7.2.2.5. Prostate Cancers
        • 7.2.2.6. Others
      • 7.2.3. Global Cancer Biopsy by: Product (Value)
        • 7.2.3.1. Instruments
        • 7.2.3.2. Kits and Consumables
        • 7.2.3.3. Services
      • 7.2.4. Global Cancer Biopsy by: End User (Value)
        • 7.2.4.1. Laboratories
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Physician Laboratories
        • 7.2.4.4. Research Centers
        • 7.2.4.5. Others
      • 7.2.5. Global Cancer Biopsy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Biopsy: by Type(USD Million)
  • Table 2. Cancer Biopsy Incisional Biopsy , by Region USD Million (2016-2021)
  • Table 3. Cancer Biopsy Excisional Biopsy , by Region USD Million (2016-2021)
  • Table 4. Cancer Biopsy Needle Biopsy , by Region USD Million (2016-2021)
  • Table 5. Cancer Biopsy: by Application(USD Million)
  • Table 6. Cancer Biopsy Breast Cancer , by Region USD Million (2016-2021)
  • Table 7. Cancer Biopsy Colorectal Cancer , by Region USD Million (2016-2021)
  • Table 8. Cancer Biopsy Cervical Cancers , by Region USD Million (2016-2021)
  • Table 9. Cancer Biopsy Lung Cancers , by Region USD Million (2016-2021)
  • Table 10. Cancer Biopsy Prostate Cancers , by Region USD Million (2016-2021)
  • Table 11. Cancer Biopsy Others , by Region USD Million (2016-2021)
  • Table 12. Cancer Biopsy: by Product(USD Million)
  • Table 13. Cancer Biopsy Instruments , by Region USD Million (2016-2021)
  • Table 14. Cancer Biopsy Kits and Consumables , by Region USD Million (2016-2021)
  • Table 15. Cancer Biopsy Services , by Region USD Million (2016-2021)
  • Table 16. Cancer Biopsy: by End User(USD Million)
  • Table 17. Cancer Biopsy Laboratories , by Region USD Million (2016-2021)
  • Table 18. Cancer Biopsy Hospitals , by Region USD Million (2016-2021)
  • Table 19. Cancer Biopsy Physician Laboratories , by Region USD Million (2016-2021)
  • Table 20. Cancer Biopsy Research Centers , by Region USD Million (2016-2021)
  • Table 21. Cancer Biopsy Others , by Region USD Million (2016-2021)
  • Table 22. South America Cancer Biopsy, by Country USD Million (2016-2021)
  • Table 23. South America Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 24. South America Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 25. South America Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 26. South America Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 27. Brazil Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 28. Brazil Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 29. Brazil Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 30. Brazil Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 31. Argentina Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 32. Argentina Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 33. Argentina Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 34. Argentina Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 35. Rest of South America Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 36. Rest of South America Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 37. Rest of South America Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 38. Rest of South America Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 39. Asia Pacific Cancer Biopsy, by Country USD Million (2016-2021)
  • Table 40. Asia Pacific Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 41. Asia Pacific Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 42. Asia Pacific Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 43. Asia Pacific Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 44. China Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 45. China Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 46. China Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 47. China Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 48. Japan Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 49. Japan Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 50. Japan Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 51. Japan Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 52. India Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 53. India Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 54. India Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 55. India Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 56. South Korea Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 57. South Korea Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 58. South Korea Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 59. South Korea Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 60. Australia Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 61. Australia Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 62. Australia Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 63. Australia Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 68. Europe Cancer Biopsy, by Country USD Million (2016-2021)
  • Table 69. Europe Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 70. Europe Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 71. Europe Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 72. Europe Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 73. Germany Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 74. Germany Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 75. Germany Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 76. Germany Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 77. France Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 78. France Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 79. France Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 80. France Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 81. Italy Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 82. Italy Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 83. Italy Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 84. Italy Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 85. United Kingdom Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 86. United Kingdom Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 87. United Kingdom Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 88. United Kingdom Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 89. Netherlands Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 90. Netherlands Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 91. Netherlands Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 92. Netherlands Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 93. Rest of Europe Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 94. Rest of Europe Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 95. Rest of Europe Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 96. Rest of Europe Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 97. MEA Cancer Biopsy, by Country USD Million (2016-2021)
  • Table 98. MEA Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 99. MEA Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 100. MEA Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 101. MEA Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 102. Middle East Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 103. Middle East Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 104. Middle East Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 105. Middle East Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 106. Africa Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 107. Africa Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 108. Africa Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 109. Africa Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 110. North America Cancer Biopsy, by Country USD Million (2016-2021)
  • Table 111. North America Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 112. North America Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 113. North America Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 114. North America Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 115. United States Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 116. United States Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 117. United States Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 118. United States Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 119. Canada Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 120. Canada Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 121. Canada Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 122. Canada Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 123. Mexico Cancer Biopsy, by Type USD Million (2016-2021)
  • Table 124. Mexico Cancer Biopsy, by Application USD Million (2016-2021)
  • Table 125. Mexico Cancer Biopsy, by Product USD Million (2016-2021)
  • Table 126. Mexico Cancer Biopsy, by End User USD Million (2016-2021)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Cancer Biopsy: by Type(USD Million)
  • Table 138. Cancer Biopsy Incisional Biopsy , by Region USD Million (2022-2027)
  • Table 139. Cancer Biopsy Excisional Biopsy , by Region USD Million (2022-2027)
  • Table 140. Cancer Biopsy Needle Biopsy , by Region USD Million (2022-2027)
  • Table 141. Cancer Biopsy: by Application(USD Million)
  • Table 142. Cancer Biopsy Breast Cancer , by Region USD Million (2022-2027)
  • Table 143. Cancer Biopsy Colorectal Cancer , by Region USD Million (2022-2027)
  • Table 144. Cancer Biopsy Cervical Cancers , by Region USD Million (2022-2027)
  • Table 145. Cancer Biopsy Lung Cancers , by Region USD Million (2022-2027)
  • Table 146. Cancer Biopsy Prostate Cancers , by Region USD Million (2022-2027)
  • Table 147. Cancer Biopsy Others , by Region USD Million (2022-2027)
  • Table 148. Cancer Biopsy: by Product(USD Million)
  • Table 149. Cancer Biopsy Instruments , by Region USD Million (2022-2027)
  • Table 150. Cancer Biopsy Kits and Consumables , by Region USD Million (2022-2027)
  • Table 151. Cancer Biopsy Services , by Region USD Million (2022-2027)
  • Table 152. Cancer Biopsy: by End User(USD Million)
  • Table 153. Cancer Biopsy Laboratories , by Region USD Million (2022-2027)
  • Table 154. Cancer Biopsy Hospitals , by Region USD Million (2022-2027)
  • Table 155. Cancer Biopsy Physician Laboratories , by Region USD Million (2022-2027)
  • Table 156. Cancer Biopsy Research Centers , by Region USD Million (2022-2027)
  • Table 157. Cancer Biopsy Others , by Region USD Million (2022-2027)
  • Table 158. South America Cancer Biopsy, by Country USD Million (2022-2027)
  • Table 159. South America Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 160. South America Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 161. South America Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 162. South America Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 163. Brazil Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 164. Brazil Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 165. Brazil Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 166. Brazil Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 167. Argentina Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 168. Argentina Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 169. Argentina Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 170. Argentina Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 171. Rest of South America Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 172. Rest of South America Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 173. Rest of South America Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 174. Rest of South America Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 175. Asia Pacific Cancer Biopsy, by Country USD Million (2022-2027)
  • Table 176. Asia Pacific Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 177. Asia Pacific Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 178. Asia Pacific Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 179. Asia Pacific Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 180. China Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 181. China Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 182. China Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 183. China Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 184. Japan Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 185. Japan Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 186. Japan Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 187. Japan Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 188. India Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 189. India Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 190. India Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 191. India Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 192. South Korea Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 193. South Korea Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 194. South Korea Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 195. South Korea Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 196. Australia Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 197. Australia Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 198. Australia Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 199. Australia Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 204. Europe Cancer Biopsy, by Country USD Million (2022-2027)
  • Table 205. Europe Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 206. Europe Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 207. Europe Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 208. Europe Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 209. Germany Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 210. Germany Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 211. Germany Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 212. Germany Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 213. France Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 214. France Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 215. France Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 216. France Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 217. Italy Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 218. Italy Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 219. Italy Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 220. Italy Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 221. United Kingdom Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 222. United Kingdom Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 223. United Kingdom Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 224. United Kingdom Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 225. Netherlands Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 226. Netherlands Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 227. Netherlands Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 228. Netherlands Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 229. Rest of Europe Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 230. Rest of Europe Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 231. Rest of Europe Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 232. Rest of Europe Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 233. MEA Cancer Biopsy, by Country USD Million (2022-2027)
  • Table 234. MEA Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 235. MEA Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 236. MEA Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 237. MEA Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 238. Middle East Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 239. Middle East Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 240. Middle East Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 241. Middle East Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 242. Africa Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 243. Africa Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 244. Africa Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 245. Africa Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 246. North America Cancer Biopsy, by Country USD Million (2022-2027)
  • Table 247. North America Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 248. North America Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 249. North America Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 250. North America Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 251. United States Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 252. United States Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 253. United States Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 254. United States Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 255. Canada Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 256. Canada Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 257. Canada Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 258. Canada Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 259. Mexico Cancer Biopsy, by Type USD Million (2022-2027)
  • Table 260. Mexico Cancer Biopsy, by Application USD Million (2022-2027)
  • Table 261. Mexico Cancer Biopsy, by Product USD Million (2022-2027)
  • Table 262. Mexico Cancer Biopsy, by End User USD Million (2022-2027)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Biopsy: by Type USD Million (2016-2021)
  • Figure 5. Global Cancer Biopsy: by Application USD Million (2016-2021)
  • Figure 6. Global Cancer Biopsy: by Product USD Million (2016-2021)
  • Figure 7. Global Cancer Biopsy: by End User USD Million (2016-2021)
  • Figure 8. South America Cancer Biopsy Share (%), by Country
  • Figure 9. Asia Pacific Cancer Biopsy Share (%), by Country
  • Figure 10. Europe Cancer Biopsy Share (%), by Country
  • Figure 11. MEA Cancer Biopsy Share (%), by Country
  • Figure 12. North America Cancer Biopsy Share (%), by Country
  • Figure 13. Global Cancer Biopsy share by Players 2021 (%)
  • Figure 14. Global Cancer Biopsy share by Players (Top 3) 2021(%)
  • Figure 15. Global Cancer Biopsy share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Qiagen N.V. (Germany) Revenue: by Geography 2021
  • Figure 19. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Illumina, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. ANGLE Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. ANGLE Plc (United Kingdom) Revenue: by Geography 2021
  • Figure 23. BD (United States) Revenue, Net Income and Gross profit
  • Figure 24. BD (United States) Revenue: by Geography 2021
  • Figure 25. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 26. Myriad Genetics (United States) Revenue: by Geography 2021
  • Figure 27. Hologic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Hologic, Inc. (United States) Revenue: by Geography 2021
  • Figure 29. Biocept, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Biocept, Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 34. Danaher (United States) Revenue: by Geography 2021
  • Figure 35. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Cancer Biopsy: by Type USD Million (2022-2027)
  • Figure 38. Global Cancer Biopsy: by Application USD Million (2022-2027)
  • Figure 39. Global Cancer Biopsy: by Product USD Million (2022-2027)
  • Figure 40. Global Cancer Biopsy: by End User USD Million (2022-2027)
  • Figure 41. South America Cancer Biopsy Share (%), by Country
  • Figure 42. Asia Pacific Cancer Biopsy Share (%), by Country
  • Figure 43. Europe Cancer Biopsy Share (%), by Country
  • Figure 44. MEA Cancer Biopsy Share (%), by Country
  • Figure 45. North America Cancer Biopsy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Qiagen N.V. (Germany)
  • Illumina, Inc. (United States)
  • ANGLE Plc (United Kingdom)
  • BD (United States)
  • Myriad Genetics (United States)
  • Hologic, Inc. (United States)
  • Biocept, Inc. (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Danaher (United States)
  • Roche Holding AG (Switzerland)
Additional players considered in the study are as follows:
Lucence (United States) , GRAIL, Inc. (United States) , Guardant Health (United States) , Others
Select User Access Type

Key Highlights of Report


Aug 2022 239 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Biopsy Market Quantitative research analysis
Global Cancer Biopsy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Cancer Biopsy Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Cancer Biopsy market is dominated by United States Players and may generate healthy valuation by 2027.
  • Improving Healthcare Infrastructure
  • Increasing Healthcare Spending
  • Increasing Number of Chronic Medical Sicknesses
dominated the Cancer Biopsy market. This is attributable to growing trend of "Needle-based Cancer Biopsy Instruments are in high demand due to their ability to collect samples from the soft tissues of internal organs such as the breasts, kidneys, and lungs"

Know More About Global Cancer Biopsy Market Report?

Have a Query? Click Here

Other Related Reports

Chlorella Tablets Comprehensive Study by Type (Supplements, Vitamins), Sodium Content (Sodium-free, Low Sodium), Category (Vitamins & Supplements, Cleansing & Detox Supplements, Energy Supplements, A...
$ 3750
Vincristine Drugs Comprehensive Study by Type (Antineoplastic, Cytotoxic), Treatment (Lymphoma, Lung Cancer, Breast & Ovarian Cancer, Leukemia, Other), End-User (Hospitals, Clinics, Diagnostic Centre...
$ 3500
Lunasin Comprehensive Study by Type (Capsule, Powder, Others), Application (Healthcare Supplements, Medical Treatments, Other), Administration (Oral, Injectable) Players and Region - Global Market Ou...
$ 3500
Vindesine Drugs Comprehensive Study by End-users (Academic & Research Institutes, Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies), Indications (Acute Leukaemia, Malignant Lympho...
$ 3650
Deuterated Drugs Comprehensive Study by Type (Austedo, Zepsun, Others), Disease (Huntington’s disease, Tardive Dyskinesia, Cancer, Others) Players and Region - Global Market Outlook to 2028
$ 3500
Carvedilol drug Comprehensive Study by Disease (Atrial Fibrillation, High Blood Pressure, Left ventricular dysfunction, Heart Failure, Angina, Others), Host (Injectable, Oral { Capsule, tablet, syrup...
$ 3450